Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | PYGB | P11216 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.34 |
| ▸ | STAT3 | P40763 | 2/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10592885 | 1.00 | SLC5A1 (0.39) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL10592883 | 1.00 | SLC5A1 (0.39) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL2047734 | 1.00 | SLC5A1 (0.39) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL23857823 | 1.00 | SLC5A1 (0.39) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL3867600 | 1.00 | SLC5A1 (0.39) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL23754212 | 1.00 | SLC5A1 (0.39) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL874627 | 1.00 | SLC5A1 (0.39) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL4257861 | 0.87 | STAT3 (0.42) | GAALGALS8STAT3SLC28A3 | |
| SCHEMBL23350541 | 0.84 | LGALS8 (0.35) | SLC5A1PYGBALDH1A1THRBCD69 | |
| SCHEMBL4257855 | 0.81 | STAT3 (0.46) | ALDH1A1THRBMAPK1GAALGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6037460-A | FOR SURFACTANTS, DETERGENTS OR EMULSIFERS ESPECIALLY COSMETIC CLEANSING AGENTS | BEIERSDORF AG (DE) | 2000-03-14 | — | — | US | claimed |
| US-20240197772-A1 | COMPOSITIONS COMPRISING ONE OR MORE HMO'S WITH A CORE OF LacNAc-Lac | FRIESLANDCAMPINA NEDERLAND B.V. (NL) | 2024-06-20 | — | — | US | disclosed |
| US-20240100075-A1 | Synthetic Compositions Comprising LNFP III and LSTa | FRIESLANDCAMPINA NEDERLAND BV (NL) | 2024-03-28 | — | — | US | disclosed |
| US-20240050585-A1 | B7-H4-TARGETED ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| WO-2023225559-A1 | B7-H4-TARGETED ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4262440-A1 | SYNTHETIC COMPOSITIONS COMPRISING LNFP III AND LSTA | FrieslandCampina Nederland B.V. (NL) | 2023-10-25 | — | — | EP | disclosed |
| CN-116568156-A | Synthetic compositions comprising LNFP III and LSTa | 菲仕兰坎皮纳荷兰公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| WO-2022129124-A9 | SYNTHETIC COMPOSITIONS COMPRISING LNFP III AND LSTA | FRIESLANDCAMPINA NEDERLAND B.V. (NL) | 2023-05-19 | — | — | WO | disclosed |
| EP-4125934-A1 | COMPOSITIONS COMPRISING ONE OR MORE HMO'S WITH A CORE OF LACNAC-LAC | FrieslandCampina Nederland B.V. (NL) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335063-A | Compositions comprising one or more HMOs having a LacNAc-Lac core | 菲仕兰坎皮纳荷兰公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022129124-A1 | SYNTHETIC COMPOSITIONS COMPRISING LNFP III AND LSTA | FRIESLANDCAMPINA NEDERLAND B.V. (NL) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021191251-A1 | COMPOSITIONS COMPRISING ONE OR MORE HMO'S WITH A CORE OF LacNAc-Lac | FRIESLANDCAMPINA NEDERLAND B.V. (NL) | 2021-09-30 | — | — | WO | disclosed |
| US-10767205-B2 | Bacterium for the production of an exopolysaccharide comprising N-acetylglucosamine and D-glucose | DePuy Synthes Products, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10633682-B2 | Bioresorbable exopolysaccharides | DePuy Synthes Products, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180258454-A1 | Bioresorbable Exopolysaccharides | SYNTHES USA PRODUCTS, LLC | 2018-09-13 | — | — | US | disclosed |
| WO-2018165077-A1 | BIORESORBABLE EXOPOLYSACCHARIDES | DePuy Synthes Products, Inc. (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2018165072-A1 | BIORESORBABLE EXOPOLYSACCHARIDES | DePuy Synthes Products, Inc. (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2014143620-A1 | SYNTHETIC LIPOAMINO ACID GLUCOSAMINE DERIVATIVES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | SLC5A1 3261/4885PYGB 390/4885ALDH1A1 4027/4885 |
| US-20240050585-A1 | B7-H4-TARGETED ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER | CD44, NECTIN4, CD274 | SLC5A1 2060/4885PYGB 4693/4885ALDH1A1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.